Evidence map›Paper›PMID 33164645›Full record

ArticleCell cycle (Georgetown, Tex.)2020

Matrine Inhibitory Effect on Self-renewal and Re-sensitization of 5-FU Resistant NSCLC Stem Cells were through Let-7b dependent Downregulation of CCND1.

Xiang Li, Meng Wang, Ning Du, Ting Liang, Guo-Dong Xiao, Kai Li, Ji-Chang Wang, Chong-Wen Xu, Zi-Yang Peng, Shou-Ching Tang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Xiang LiDepartment of Thoracic Surgery and Oncology, The Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.
Meng WangDepartment of Thoracic Surgery and Oncology, The Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.
Ning DuDepartment of Thoracic Surgery and Oncology, The Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.
Ting LiangDepartment of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.
Guo-Dong XiaoDepartment of Thoracic Surgery and Oncology, The Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.ORCID 0000-0002-8739-5513
Kai LiDepartment of Thoracic Surgery and Oncology, The Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.
Ji-Chang WangDepartment of Vascular and Endovascular Surgery, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.
Chong-Wen XuDepartment of Otorhinolaryngology, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.
Zi-Yang PengDepartment of Thoracic Surgery and Oncology, The Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.
Shou-Ching TangUniversity of Mississippi Medical Center, Cancer Center and Research Institute, University of Mississippi , Jackson, Mississippi, USA.
Xin SunDepartment of Thoracic Surgery and Oncology, The Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, Shaanxi, P.R.China.ORCID 0000-0001-5909-5786
First Affiliated Hospital of Xi'an Jiaotong University · CNMinistry of Education of the People's Republic of China · CNUniversity of Mississippi Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrine is one of the major alkaloids extracted from Sophora flavescens Ait of the traditional Chinese medicine, was the main chemical ingredient of compounds of Kushen injection. The Matrine is considered as a promising therapeutic agent for curing nonsmall cell lung cancer (NSCLC), used either alone or combined with chemotherapeutic agents. In the present study, we focused on the possible roles of Matrine exerted on the self-renewal ability of stem-like cells of the NSCLC group, as well as the cytotoxicity of chemotherapeutic agents, in vitro and in vivo. Here we reported that Matrine inhibits cancer stem-like cell (CSC) properties through upregulation of Let-7b and suppression of the Wnt pathway. Overexpression of Let-7b suppressed the ability of tumorsphere formation, decreased Wnt pathway activation through inhibiting its transcriptional activity in lung CSCs. Further studies revealed that Let-7b directly targeted CCND1 and decreased its expression, whereas Matrine increased Let-7b levels and followed by inactivation of the CCND1/Wnt signaling pathway and inhibition of EMT, which was characterized by loss of epithelial markers and acquisition of a mesenchymal phenotype in lung CSCs. What is more, we found that Matrine increased Let-7b level in an endoribonuclease DICER1-dependent manner. And xenografts in nude mice evidenced that Matrine increased the sensitivity of lung CSCs to 5-FU and inhibited the accumulation of CCND1 in tumor tissues induced by 5-FU. Taken together, these data illustrate the role of Let-7b in regulating lung CSCs traits and DICER1/let-7/CCND1 axis in Matrine or in combination with 5-FU intervention of lung CSCs' expansion, helping to fulfill the anti-cancer action of Matrine.

Indexed as

A549 CellsAlkaloidsAnimalsAntimetabolites, AntineoplasticCarcinoma, Non-Small-Cell LungCyclin D1Down-RegulationDrug Resistance, NeoplasmFluorouracilHumansLung NeoplasmsMaleMatrinesMiceMice, Inbred BALB CMice, NudeAlkaloidsAntimetabolites, AntineoplasticCCND1 protein, humanCyclin D1FluorouracilMatrinesMicroRNAsmirnlet7 microRNA, humanQuinolizinescancer stem cellsdivision mannersMatrineNSCLCtherapy resistance

Identifiers

PMID33164645
PMCPMC7751667
OpenAlexW3103854553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.